Islet amyloid polypeptide is a normal constituent of islet Beta cells and is derived from a larger precursor by removal of flanking peptides at the carboxy (C) and amino (N) terminals. The role of these flanking peptides in the formation of amyloid in Type2 (non-insulin-dependent) diabetes mellitus and in insulinomas is unknown. The C-terminal flanking peptide of islet amyloid polypeptide was localised by immunocytochemistry in human and monkey pancreatic islets from Type 2 diabetic and non-diabetic individuals by use of specific polyclonal antisera. Immunoreactivity for the C-terminal peptide was found in insulincontaining cells in both diabetic and non-diabetic tissue: no antibody binding was detected in islet amyloid of Type 2 diabetic man or of monkeys although a positive reaction occurred with antisera for islet amyloid polypeptide. The C-terminal peptide was localised by immunogold electron microscopy in the insulin granules in both diabetic and nondiabetic individuals but, unlike islet amyloid polypeptide, was not detected in lysosomes. The absence of immunoreactivity for the C-terminal peptide in amyloid suggests that incomplete cleavage of this flanking peptide from islet amyloid polypeptide is not a factor in the formation of islet amyloid.
Islet amyloid is formed in Type 2 (non-insulin-dependent) diabetes mellitus and in insulinomas from a 37 amino acid peptide, islet amyloid polypeptide (IAPP) [1] . This peptide is a normal component of diabetic and non-diabetic Beta cells where it is located in insulin granules and lysosomes [2] . Analysis of the encoding cDNA suggests that IAPP is derived from a larger propeptide (89 amino acids in man) by proteolytic cleavage [3] . However, little is known about the processing pathway of IAPP in the Beta cell under normal conditions and in diabetes.
It is unlikely that amyloid develops as a result of genetically determined amino acid substitution of IAPP in Type 2 diabetes [4] . Abnormal cleavage of the propeptide may be involved since immunoreactivity for the Nterminal flanking peptide (pro-IAPPas-3o) has been identified in the amyloid deposits [5] . Alternatively, this small peptide may, like amyloid P component and glycated proteins, adhere to the previously formed fibrils. Involvement of the C-terminal flanking peptide. (C-IAPP) in islet amyloidosis was examined with immunocytochemistry in tissue from non-diabetic and diabetic man and monkey.
Materials and methods

Antisera production
The C-terminal flanking peptide of IAPP (20 amino acids) with the sequence Gly, Lys, Arg, Asn, Ala, Val, Glu, Val, Leu, Lys, Arg, Glu, Pro, Leu, Asn, Tyr, Leu, Pro, Leu, was synthesised by automatic solid phase synthesis (model 431A, Applied Biosystems, Warrington, UK). An N-terminal cysteine was added to permit conjugation to a hapten for antibody production. C-IAPP was conjugated to keyhole limpet haemocyanin by use of a hetero-bifunctional linkage using m-maleimidobenzoyl-N-hydroxysuccinimide. Rabbits were immunised with the conjugated peptide in Freund's complete adjuvant. The resulting antisera cross-reacted with the non-conjugated peptide on ELISA plates coated with 2 gg/ml of the peptide. These antisera did not cross-react with IAPPI_3v or IAPE NH2]_37 (2 gg/ml) on ELISA plates. The specificity of the antibody for immunohistochemistry was confirmed by preabsorption of the diluted antibody with 10 gg/ml of the unconjugated C-IAPR No immunoreactivity was found after preabsorptiou.
Specimens
Postmortem pancreas specimens were examined from 14 Type 2 diabetic subjects with islet amyloid (aged 48-89 years), 10 nondiabetic patients (aged 40-78 years), two obese diabetic Macaca and embedded in paraffin wax. Tissue for electron microscopy was fixed in 2% paraformaldehyde, 0.5% glutaraldehyde in 0.1 mol/l cacodylate buffer, pH 7.2, and embedded in LR gold resin (Taab Laboratories, Aldermaston, UK).
Irnrnunohistochernistcv lmmunoreactivity for C-IAPR lAPP and insulin was examined light microscopically with immunoperoxidase and antisera to insulin (diluted 1:1000) raised in a guinea pig, or to IAPP7 37 (diluted 1:1000) and C-lAPP (diluted 1:1000) raised in rabbits. Co-localisation of insulin and C-IAPP was examined by double labelling on the same section with fluorescein-conjugated (FITC) anti-guinea pig antiserum (Dako, High Wycombe, UK) (for insulin) and peroxidase conjugated anti-rabbit antiserum (Dako) (for C-IAPP). Immunoreactivity was detected electron microscopically by incubation of ultrathin sections mounted on nickel grids with primary antisera at 1:500 dilution (anti-IAPP and anti-C-IAPP) or 1:1000 (anti-insulin) followed by protein-A gold (ICN, High Wycombe, UK) 
Results and Discussion
Immunoreactivity in islet arnyloid. Immunoreactivity for C-IAPP was not detected in islet amyloid (Fig. 1 a) of any specimen of diabetic human or monkey pancreas even though a positive staining reaction for IAPP7_37 was present ( Fig. 1 b) . This suggests that C-IAPP is not part of the structure of the amyloid fibrils. Although IAPPl_37 was identified as the major constituent of amyloid in the extracted samples of pancreatic tissue [1] , the presence of pro-IAPP (or other fragments of pro-IAPP) in amyloid could not be excluded. Incomplete processing of procalcitonin at both the C-and N-terminals has been implicated in the amyloidosis associated with medullary carcinomas of the thyroid [6, 7] .
Imrnunoreactivity in islet cells. The C-terminal peptide was detected in islet cells of diabetic and non-diabetic individuals (Fig. I c) which were identified as Beta cells by double labelling experiments. The density of the staining reaction for C-IAPP was not uniform in all Beta cells (Fig. 1 c) : a dense peroxidase reaction was present in a small number (approximately 30% of Beta cells) of Beta cells and a similar population of cells showed immunoreactivity for IAPP (Fig. ld) . Electron microscopy demonstrated immunogold labelling of C-IAPP located over insulin granules in Beta cells of both diabetic and non-diabetic individuals (Fig. 2) but not over amyloid deposits in a diabetic monkey. Furthermore, no labelling for C-IAPP could be detected in lysosomes or lipofuscin bodies in Beta cells although these showed positive immunoreactivity for IAPP on serial ultrathin sections. As with light microscopy, no labelling for C-IAPP was found in glucagon-, pancreatic polypeptideor somatostatin-containing cells.
The biosynthetic pathway for IAPP is unknown, but the presence of Lys Arg sequences suggests that proteolytic cleavage of pro-IAPP similar to that of proinsulin is involved [8] . Elevated levels of proinsulin have been found in patients with insulinomas and Type 2 diabetes mellitus and also in a subject known to have islet amyloid [9] implying that abnormal processing of B eta cell products could be implicated in amyloid formation in these conditions.
